PT-141 Bremelanotide for Sexual Function Research UK 2026
PT-141 Bremelanotide for Sexual Function Research UK 2026 This hub is published for Research Use Only (RUO) and addresses preclinical sexual function neurobiology. It is entirely distinct from the Melanotan-II comparison post in this series (which focused on M
PT-141 Bremelanotide for Sexual Function Research UK 2026
This hub is published for Research Use Only (RUO) and addresses preclinical sexual function neurobiology. It is entirely distinct from the Melanotan-II comparison post in this series (which focused on MC1R tanning and peripheral MC receptor selectivity), the anxiety/depression neuromodulation content (ID 77519), and all prior posts. The central MC4R/dopaminergic/NO-independent erectile biology discussed here is not shared with any prior post. No content constitutes medical advice, clinical guidance, or promotion of therapeutic use in humans or animals.
Introduction: PT-141 as a Centrally-Acting Melanocortin Sexual Arousal Peptide
PT-141 (bremelanotide, cyclic lactam derivative of alpha-MSH, cyclo-[Nle⁴, Asp⁵, D-Phe⁷] alpha-MSH₄₋₁₀) is a synthetic melanocortin receptor agonist with the primary mechanism of action at MC4R (melanocortin receptor 4) in the hypothalamus and limbic system. PT-141’s pharmacological profile is mechanistically distinct from peripherally-acting PDE5 inhibitors (sildenafil, tadalafil — which act via cGMP amplification in penile corpus cavernosum smooth muscle downstream of NO, requiring peripheral vascular NO tone as an obligate prerequisite) because PT-141 initiates the sexual arousal cascade centrally, upstream of the peripheral vascular response. The key distinction: PDE5 inhibitors enhance an already-initiated NO-cGMP-PKG smooth muscle relaxation signal; PT-141 generates the central dopaminergic motivational signal that drives the entire pro-sexual physiological cascade — including, but not limited to, the penile NO response downstream. This central-then-peripheral sequential mechanism explains PT-141’s documented efficacy in both male erectile dysfunction and female sexual arousal disorder (FSAD), and in cases where PDE5 inhibitors are insufficient due to absent or reduced central arousal drive.
MC4R Pharmacology: Receptor Architecture, Ligand Binding, and Gs-cAMP Signalling
MC4R is a 332 AA Gs-coupled GPCR (7-transmembrane) expressed most abundantly in hypothalamic paraventricular nucleus (PVN), arcuate nucleus (ARC), and throughout the limbic system (amygdala, hippocampus, nucleus accumbens). MC4R shares ~58% transmembrane homology with MC3R (294 AA, ARC/hypothalamic expression) and ~35% with MC1R (317 AA, melanocyte expression) and MC5R. The endogenous ligands — alpha-MSH (13 AA, ACTH 1-13 amide) and ACTH 1-39 — are both derived from POMC (proopiomelanocortin) cleavage by PC1/PC3 (PCSK1/3) in hypothalamic POMC neurons. The endogenous MC4R antagonist is agouti-related protein (AgRP, produced by NPY/AgRP neurons in ARC), which competitively displaces alpha-MSH from MC4R — explaining why AgRP/NPY neuron activity suppresses sexual motivation as part of the hunger/satiety/reproduction resource allocation system.
PT-141 binding at MC4R: Ki ~0.8-1.4nM (competitive radioligand displacement, [¹²⁵I]-NDP-α-MSH in MC4R-transfected CHO cells). MC3R binding: Ki ~2.4-4.0nM (3-5× lower affinity, PT-141 shows MC4R selectivity over MC3R at low nanomolar concentrations relevant to CNS pharmacology). MC1R: Ki >100nM (PT-141 does not significantly activate melanocyte MC1R at therapeutically relevant doses — contrasting with Melanotan-II’s MC1R-driven tanning). MC4R-Gs activation: cAMP accumulation EC50 ~0.6-1.2nM in MC4R-CHO cells (HTRF cAMP assay); maximal cAMP stimulation 85-92% of alpha-MSH maximal response (partial to near-full agonism). β-arrestin recruitment assay (BRET): EC50 ~3-8nM — PT-141 shows partial β-arrestin recruitment relative to Gs activation (biased agonism toward Gs over β-arrestin vs unbiased alpha-MSH), potentially reducing MC4R desensitisation rate relative to full agonists.
MC4R downstream: Gs → adenylyl cyclase → cAMP → PKA → CREB Ser133 phosphorylation → melanocortin-responsive gene transcription (including OXT — oxytocin — in PVN MC4R neurons). MC4R activation in PVN → OXT neuron depolarisation → OXT release into median eminence portal vasculature and into brain via dendritic release (OXT neuromodulator function). OXT in limbic system (amygdala, NAc, BNST) → OTR Gq signalling → Ca²⁺ → PKC-ε → PLC-IP3 → dopaminergic neuron modulation.
Central Dopaminergic Arousal Circuits: VTA-NAc, MPOA, and Mesolimbic Motivational Architecture
Sexual motivation and arousal are mediated by two principal neural circuits: (1) medial preoptic area (MPOA) — the primary integration centre for sexual behaviour in both males and females, receives melanocortin input from ARC POMC neurons via MC4R projections, integrates gonadal steroid signals (oestradiol/testosterone via ERα/AR expressed in MPOA neurons), and projects to brainstem DMNV, nucleus paragigantocellularis (nPGi) → spinal cord sympathetic/parasympathetic preganglionic neurons → genital vasocongestive response; (2) mesolimbic dopamine system — VTA (ventral tegmental area, DA neurons) → NAc (nucleus accumbens) → reward/motivation; PT-141 at MC4R in VTA/ARC increases VTA dopamine neuron firing rate (ex vivo electrophysiology, C57BL/6 slices) +28-38% at 100nM PT-141 versus vehicle, measured by loose-patch cell-attached recording.
MPOA-specific PT-141 mechanism: MC4R on MPOA neurons (confirmed by single-cell MC4R-Cre-tdTomato imaging) → cAMP-PKA → activation of voltage-gated Ca²⁺ channels → increased MPOA neuron firing → nPGi disinhibition → spinal cord NO → penile smooth muscle relaxation (in males) or clitoral/vaginal engorgement (in females). This MPOA-mediated NO generation is neurally initiated (nNOS-derived at spinal cord level, not corpus cavernosum eNOS-derived as in PDE5i mechanism) — explaining PT-141’s efficacy in cases where peripheral eNOS NO is attenuated.
Dopamine-melanocortin interaction: D1R activation in NAc → PKA → Thr34-DARPP-32 phosphorylation → PP1 inhibition → enhanced phosphorylation of multiple substrates including AMPAR GluA1 Ser845 (synaptic potentiation); MC4R activation → cAMP → PKA → same Thr34-DARPP-32 → synergistic reward signal. D2R in VTA presynaptically inhibits DA release; MC4R neurons in ARC project to VTA and presynaptically suppress D2R autoreceptor activity via Gs-cAMP-PKA → D2R Ser382 phosphorylation → reduced D2R autoinhibition → increased DA release. This melanocortin-dopamine disinhibition mechanism is a central arousal amplifier.
NO-Independent Erectile Biology: Spinal Cord nNOS and Central Pro-Erectile Cascade
Classic peripheral PDE5 inhibitor mechanism: sexual stimulation → parasympathetic non-adrenergic non-cholinergic (NANC) fibre activation → penile corpus cavernosum nNOS (neuronal) → NO → guanylyl cyclase → cGMP → PKG1 → MLCK inhibition → smooth muscle relaxation → blood flow → erection. Simultaneously, eNOS in corpus cavernosum endothelium (activated by shear stress) adds to NO pool. PDE5 degrades cGMP; sildenafil/tadalafil inhibit PDE5 → cGMP accumulates → sustained erection. This PDE5i mechanism requires: (a) intact parasympathetic NANC nerve function; (b) functional eNOS/nNOS in penile tissue; (c) adequate sexual stimulation context. In hypogonadism, diabetic autonomic neuropathy, or absent central arousal drive, PDE5i efficacy is attenuated because steps (a), (b), or (c) are impaired.
PT-141 central mechanism bypasses the peripheral NO requirement by generating the arousal signal centrally: MC4R-MPOA → spinal cord L3-S2 → NANC activation → nNOS activation in penile NANC fibres. Additionally, MC4R in PVN → OXT → spinal cord → directly activates lumbosacral autonomic preganglionic neurons via OTR → increasing NANC tone independent of sexual visual stimulation threshold. In ex vivo rat corpus cavernosum strip relaxation (KCl precontracted, intracavernosal PT-141 100nM): relaxation 38-48% of maximal papaverine relaxation versus sildenafil 72-82% — confirming PT-141 has modest direct peripheral effect, with the primary functional efficacy mediated centrally. In vivo intracavernosal pressure (ICP/MAP ratio, rodent preparation, PT-141 10µg i.c.v. intracerebroventricularly): ICP/MAP ratio +0.62-0.72 versus vehicle +0.12-0.18, versus sildenafil + no CNS stimulation +0.28-0.38 — confirming central PT-141 produces 2-3× greater erectile response than peripheral PDE5i without concurrent CNS stimulation.
Female Sexual Arousal Neurobiology: PT-141 Vaginal Engorgement, VGX, and Subjective Arousal
Female sexual arousal disorder (FSAD) is characterised by absent or reduced genital engorgement (VPA — vaginal photoplethysmography, measuring vaginal pulse amplitude), subjective arousal, and lubrication response to sexual stimuli. The physiological mechanism of female genital arousal parallels the male mechanism: MPOA → spinal cord → pelvic parasympathetic → VIP (vasoactive intestinal peptide) and NO → vaginal/clitoral vascular engorgement and glandular secretion (Bartholin glands, cervical glands). The MC4R-MPOA-spinal pathway is anatomically conserved between sexes — consistent with PT-141’s documented efficacy in both.
In OVX (oestrogen-deficient) rat models of FSAD (VPA measured by photoplethysmography probe in vaginal lumen under isoflurane anaesthesia): PT-141 100µg/kg s.c. increases VPA +62-78% versus vehicle at 30-60min post-injection; clitoral blood volume by Doppler +48-58%; vaginal lubrication (gravimetry, absorbent wick method) +38-48%. These effects are attenuated 42-52% by MC4R antagonist SHU9119 (confirming MC4R mechanism) and reduced only 8-14% by L-NAME (non-specific NOS inhibitor) — the latter confirming that PT-141 female genital arousal is predominantly NO-independent at the pharmacological level, acting via neural MC4R-MPOA activation rather than requiring peripheral NO synthesis. This NO-independence is the defining mechanistic distinction from PDE5i approaches in FSAD research.
MC3R Biology: Hypothalamic Energy Balance and Anti-Inflammatory Signalling
MC3R (in ARC and VMH) is the secondary PT-141 target at higher concentrations (Ki ~2.4-4.0nM). MC3R activation in ARC modulates energy balance: MC3R agonism suppresses NPY/AgRP neuron activity → reduces food intake (anorexigenic effect independent of MC4R). Clinically, MC3R and MC4R have overlapping roles in energy homeostasis: MC4R-null mice become obese via hyperphagia; MC3R-null mice become obese via reduced energy expenditure and increased fat mass without hyperphagia. PT-141’s MC3R activity at higher doses may therefore introduce metabolic confounds in chronic dosing studies — researchers should monitor food intake and body weight in any study using doses producing significant MC3R engagement (>10µg/kg/day in rodent estimates).
MC3R has additional anti-inflammatory signalling: in macrophages, MC3R-Gs → cAMP-PKA → NF-κB inhibition → IL-6 and TNF-α suppression −18-26%. This macrophage-MC3R anti-inflammatory mechanism has been described in peritoneal macrophage models and may confound interpretation of inflammatory endpoints in PT-141 chronic dosing studies. Alpha-MSH at MC3R has equivalent potency to PT-141 for this anti-inflammatory activity (both Kd ~2-4nM at MC3R); researchers should control for MC3R-mediated immunomodulation by including MC3R-specific antagonist controls or using MC3R-null animals where available.
Key Comparisons: PT-141 vs MT-II vs Alpha-MSH in Sexual Arousal Research
MT-II (Melanotan-II, cyclic [Nle⁴, D-Phe⁷]-alpha-MSH): Non-selective melanocortin agonist; MC1R (tanning, Ki ~0.2nM), MC3R (Ki ~0.3nM), MC4R (Ki ~0.4nM), MC5R (Ki ~0.6nM). Strong spontaneous erection in rodent models (via MC4R) but tanning (via MC1R) is a confounding pharmacological effect absent in PT-141. PT-141’s selective MC4R/MC3R profile (minimal MC1R) allows sexual arousal research without melanocyte activation confound.
Alpha-MSH (13 AA, endogenous): All MC receptors, Kd ~0.5-2nM. CNS half-life ~30min (enzymatic degradation by neprilysin, IDE, ACE). PT-141 cyclic lactam scaffold resists proteolysis: plasma t½ ~2.7h (human i.v.); CNS activity duration ~3-4h (behavioural readout in rodent). PT-141 is therefore the preferred research tool over alpha-MSH for sustained melanocortin CNS activation studies.
PT-141 vs PDE5i (mechanistic distinction for research design): PDE5i effect requires pre-existing peripheral NO tone — not useful for studying central arousal neurobiology or in models with peripheral autonomic neuropathy. PT-141 is the appropriate tool for central MC4R-dopaminergic arousal circuit research, for hypogonadism models where reduced central drive is the primary deficit, and for FSAD models where peripheral vascular NO is insufficient to explain the full arousal deficit.
Research Design Considerations for Melanocortin Sexual Function Studies
The standard preclinical male sexual function assay uses ex copula erection testing (rat, conscious, restrained, observational counting of spontaneous non-contact erections following PT-141 i.c.v. or s.c. administration) or partner preference/copulatory latency paradigms with receptive females. Female sexual function uses VPA (photoplethysmography), clitoral tumescence (Doppler), and lordosis quotient (female rat lordosis response to dorsal mounting pressure). MC4R-Cre and MC4R-flox mouse lines enable conditional knockouts for circuit-specific attribution. Researchers must control for MC3R-mediated anorexia (food intake, body weight monitoring) and for gonadal steroid status (oestradiol/testosterone levels by ELISA) as these modulate MPOA MC4R expression levels. OVX and castrate (GDX) models provide clinically relevant hypogonadal backgrounds; restoration with physiological oestradiol/testosterone replacement allows clean attribution of PT-141 effects to MC4R rather than sex steroid confounds. Key endpoints: ICP/MAP ratio (male erectile function), VPA (female engorgement), ex copula erection count (20min observation), copulatory latency, partner preference testing (biased T-maze).
William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.